Business
Viking Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, March 8, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, March 8, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will present at two upcoming investor conferences. \n\n \n \n \n \n \n \n\n \nDetails of the company's participation are as follows:\n34th Annual Roth ConferenceDetails: Brian Lian, Ph.D., chief executive officer of Viking, will participate in a fireside chat and Viking management will participate in 1-on-1 meetingsConference Dates: March 13-15, 2022Fireside Chat Time: 9:00 a.m. Pacific on Tuesday, March 15, 2022Format: Hybrid conference with both in-person and virtual participation Oppenheimer 32nd Annual Healthcare ConferenceDetails: Dr. Lian will deliver a corporate presentation and Viking management will participate in 1-on-1 meetingsConference Dates: March 15-17, 2022Presentation Time: 11:40 a.m. Pacific on Wednesday, March 16, 2022Format: Virtual conference; webcast availableA live webcast of the Oppenheimer presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conferences. \nAbout Viking Therapeutics, Inc. \nViking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's second clinical candidate is VK0214, a novel, orally available...